Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer (vol 76, pg 2301, 2016)

被引：0
|
作者：
Herrera-Abreu, Maria Teresa
Palafox, Marta
Asghar, Uzma
Rivas, Martin A.
Cutts, Rosalind J.
Garcia-Murillas, Isaac
Pearson, Alex
Guzman, Marta
Rodriguez, Olga
Grueso, Judit
Bellet, Meritxell
Cortes, Javier
Elliott, Richard
Pancholi, Sunil
Lord, Christopher J. [1 ,2 ]
Baselga, Jose
Dowsett, Mitch
Martin, Lesley-Ann
Turner, Nicholas C.
Serra, Violeta
机构：
[1] Inst Canc Res, CRUK Gene Funct Lab, London, England
[2] Inst Canc Res, Breast Canc Now Res Ctr, London, England
来源：
CANCER RESEARCH | 2016年 / 76卷 / 19期
关键词：
D O I：
10.1158/0008-5472.CAN-16-1853
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5907 / 5907
页数：1
相关论文
共 50 条
  • [41] Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer
    Olesya A. Kharenko
    Reena G. Patel
    Cyrus Calosing
    Edward H. van der Horst
    Cancer Gene Therapy, 2022, 29 : 859 - 869
  • [42] Combined inhibition of CDK2 and CDK4/6 overcomes acquired resistance to CDK4/6 inhibitors in breast cancer via RB-independent pathway
    Pandey, Kamal
    CANCER RESEARCH, 2020, 80 (16)
  • [43] Combination mTORC1/2 and BCL- XL inhibition in endocrine and CDK4/6-resistant estrogen receptor-positive breast cancer.
    Sammons, Sarah
    Anderson, Grace
    Wardell, Suzanne
    McDonnell, Donald P.
    Marcom, Paul Kelly
    Wood, Kris
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] CRISPR screen identifies GATAD1 as a synthetic lethal target with CDK4/6 inhibitors in estrogen receptor-positive breast cancer
    Liu, Wenqiang
    Zhang, Ruhua
    Yu, Xinhao
    Zhang, Yu
    Kang, Tiebang
    Liao, Dan
    MEDICAL ONCOLOGY, 2023, 40 (09)
  • [45] Identification of CDK4/6-response biomarkers using estrogen receptor-positive breast cancer patient-derived xenografts (PDX)
    Palafox, M.
    Herrera, M. T.
    Bellet, M.
    Arribas, J.
    Saura, C.
    Di Tomaso, E.
    Turner, N. C.
    Cortes, J.
    Baselga, J.
    Serra, V.
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : S134 - S134
  • [46] IN VIVO MODELING OF ACQUIRED DRUG RESISTANCE: GBM ADAPTATION TO SUSTAINED cdk4/6 INHIBITION
    Lu, Yu-Jen
    De La Torre, Jacqueline
    Waldman, Todd
    Prados, Michael
    Ozawa, Tomoko
    James, David
    NEURO-ONCOLOGY, 2013, 15 : 51 - 51
  • [47] CRISPR screen identifies GATAD1 as a synthetic lethal target with CDK4/6 inhibitors in estrogen receptor-positive breast cancer
    Wenqiang Liu
    Ruhua Zhang
    Xinhao Yu
    Yu Zhang
    Tiebang Kang
    Dan Liao
    Medical Oncology, 40
  • [48] Identification of CDK4/6-response biomarkers using estrogen receptor-positive breast cancer patient-derived xenografts (PDX)
    Serra, Violeta
    Palafox, Marta
    Herrera, Maria-Teresa
    Rivas, Martin A.
    Guzman, Marta
    Rodriguez, Olga
    Grueso, Judit
    Bellet, Meritxell
    Oliveira, Mafalda
    Saura, Cristina
    di Tomaso, Emmanuelle
    Camponigro, Giordi
    Turner, Nicholas C.
    Cortes, Javier
    Baselga, Jose
    CANCER RESEARCH, 2016, 76
  • [49] CDK4/6 Inhibitor Resistance in Hormone Receptor-Positive Metastatic Breast Cancer: Translational Research, Clinical Trials, and Future Directions
    Lee, Jin Sun
    Hackbart, Hannah
    Cui, Xiaojiang
    Yuan, Yuan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (14)
  • [50] Mechanisms of Resistance to CDK4/6 Inhibitors in Hormone Receptor-Positive (HR plus ) Breast Cancer: Spotlight on Convergent CDK6 Upregulation and Immune Signaling
    Brett, Jamie O.
    Herman, Paige E.
    Mayer, Erica L.
    Bardia, Aditya
    Wander, Seth A.
    CURRENT BREAST CANCER REPORTS, 2022, 14 (04) : 222 - 232
12345